In a significant milestone for the biotechnology sector, Ann Arbor-based Sling Therapeutics has announced the successful closure of a $123 million Series C financing round. The capital injection, led by Forbion with participation from TPG Life Sciences Innovations and Sectoral Asset Management, serves as a powerful endorsement of the company’s lead asset, linsitinib. As a clinical-stage biotech, Sling is positioning this oral small molecule to disrupt the current treatment landscape for thyroid eye disease (TED), an autoimmune condition that causes debilitating swelling and protrusion of the eyes.
The funding arrives at a pivotal moment for the TED market, which has seen a flurry of research activity even as established players navigate the challenges of clinical development. With $200 million in total funding raised since its 2022 inception, Sling is now accelerating its global Phase 3 “Orbit” trial, aiming to provide patients with a more convenient and potentially safer alternative to existing biologics.
The Landscape: A High-Stakes Race for TED Therapies
Thyroid eye disease, often associated with Graves’ disease, is an inflammatory condition that can lead to significant physical and psychological burden. The standard of care has historically relied on antibody-based therapies, most notably Amgen’s Tepezza and the recently approved Lumvoa from Viridian Therapeutics.
The Challenge of Current Standards
While these antibody treatments target the insulin-like growth factor-1 receptor (IGF-1R) to mitigate inflammation, they come with substantial administrative and safety hurdles. Because they are biologics, they must be administered via intravenous infusion or subcutaneous injection, often requiring patients to make regular clinical visits. Furthermore, these therapies have been associated with notable side effects, including hyperglycemia, potential fertility impacts, and, in some cases, persistent hearing loss or tinnitus.
A Fragmented Competitive Field
The market is currently characterized by a mix of high-profile successes and notable failures. Companies like Immunovant and Argenx have seen their prospective candidates encounter setbacks in late-stage testing, highlighting the difficulty of targeting the IGF-1R pathway safely and effectively. Meanwhile, new entrants like Ethyreal Bio and Khartis are scrambling to secure a foothold, creating a highly competitive environment where only the most robust clinical profiles are likely to achieve long-term commercial success.
Chronology: From Oncology Assets to Ocular Innovation
Sling Therapeutics’ journey is a study in the strategic repurposing of pharmaceutical assets. The company’s story is rooted in the recognition that a drug’s failure in one therapeutic area does not preclude its success in another.
- Pre-2022: Linsitinib is developed and tested by Astellas Pharma across more than a dozen oncology indications. While it failed to achieve breakthrough status in cancer treatment, its safety profile and mechanism of action were well-documented.
- 2022: Sling Therapeutics launches with a $35 million Series A financing round, officially licensing linsitinib from Astellas. By leveraging pre-existing safety data from the oncology trials, the company bypasses years of early-stage toxicology studies.
- January 2025: The company reports positive topline results from its Phase 2b/3 “LIDS” clinical trial. The study demonstrates a 52% response rate at 24 weeks, providing the primary evidence needed to justify a large-scale global Phase 3 study.
- Wednesday Morning: Sling announces its $123 million Series C round, signaling the transition to a late-stage company focused on regulatory approval and commercial readiness.
Supporting Data: Why Oral Administration Matters
The core value proposition of linsitinib lies in its delivery method. As an oral small molecule, it offers a level of patient convenience that injectable biologics simply cannot match. Ryan Zeidan, President and CEO of Sling Therapeutics, emphasizes that the convenience factor is not just about comfort—it is about patient adherence and quality of life.
Clinical Performance and Safety Profile
The data emerging from the LIDS trial suggests that linsitinib achieves its goals through a more precise interaction with the IGF-1R protein. In oncology trials, small molecules that targeted IGF-1R often hit multiple biological pathways, leading to the toxicities that eventually halted their development for cancer. Sling’s clinical team argues that linsitinib is more selective.
In the Phase 2b/3 trial:
- Efficacy: A 52% response rate was recorded after 24 weeks of twice-daily dosing.
- Safety: Most notably, the trial reported no drug-related cases of hearing loss or tinnitus—a significant point of differentiation from existing FDA-approved biologics.
- Durability: Early indications suggest that the clinical benefit of the small molecule may prove more durable than that of antibody-based therapies, potentially reducing the frequency of follow-up treatments.
Official Responses and Strategic Vision
The investment community’s support is anchored in the belief that Sling has found a "goldilocks" solution: a proven mechanism of action delivered in a more patient-friendly format.
"Our continued investment into Sling reflects our confidence in the team’s execution and in linsitinib’s potential to meaningfully improve the treatment paradigm for TED patients," said Peter Bojo, a principal at TPG Life Sciences, in a formal statement.
For his part, Ryan Zeidan remains focused on the "Orbit" trial, but his vision extends beyond the current indication. During a discussion with BioPharma Dive, Zeidan outlined the potential for expanding into earlier stages of the disease or tackling chronic TED. "We have some really interesting commercial expansion opportunities and new patient indications that would benefit from this drug, that are unique to a small molecule oral therapeutic," he stated.
Implications: The Future of TED Treatment
The potential approval of an oral TED therapy would represent a paradigm shift in ocular immunology. If the "Orbit" trial confirms the results of the LIDS study, Sling Therapeutics could effectively move the treatment of thyroid eye disease out of the infusion suite and into the home.
Implications for Patients
For patients, the transition from an infusion-based therapy to a twice-daily pill would significantly reduce the logistical burden of treatment. Patients would no longer be tethered to infusion centers, potentially increasing the number of individuals who seek treatment early in the progression of the disease.
Implications for the Market
The pharmaceutical industry is watching closely. If linsitinib succeeds, it will force a re-evaluation of the "biologics-first" approach that has dominated the inflammatory disease space for the last decade. Furthermore, it validates the strategy of "drug rescue"—taking assets that were discarded in the high-risk oncology space and applying them to conditions where the therapeutic pathway is better understood.
The Road Ahead
While the $123 million provides a long runway for the Orbit trial, the path to market is never without risk. The company must successfully navigate the FDA’s rigorous scrutiny regarding the long-term safety profile of the drug. While the lack of hearing loss in initial trials is promising, regulatory bodies will require extensive longitudinal data to ensure that the systemic exposure of a twice-daily small molecule does not introduce unforeseen long-term adverse events.
Sling Therapeutics now stands at the threshold of becoming a commercial-stage company. With the scientific community closely monitoring the Orbit trial, the coming months will likely be defined by the company’s ability to translate its clinical data into a compelling argument for patients, physicians, and eventually, insurers. Should they succeed, the landscape of thyroid eye disease will be irrevocably altered, favoring the convenience and precision of oral small molecules over the traditional antibody-based approaches of the past.
